Do higher doses of Wegovy produce better weight loss results?

What the trial data actually show about dose and weight loss

The relationship between dose and outcome in semaglutide trials is not a guess, it follows a consistent pattern. In STEP 1, participants who reached and maintained 2.4 mg lost roughly 15% of body weight on average over 68 weeks alongside lifestyle changes, far outpacing placebo. Importantly, the titration steps before that point (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg) were not intended to be stopping places for most people; they are tolerability rungs designed to let the body adjust gradually, with meaningful weight loss building as the dose climbs.

The 7.2 mg Wegovy dose takes this further. Trials at that level reported approximately 20.7% average weight reduction over 72 weeks. That result starts to close the gap with tirzepatide at its highest dose, making the dose choice between the two medicines a more nuanced clinical conversation than it was even two years ago. The MHRA's approval of a dedicated single-dose 7.2 mg pen on 14 April 2026 means patients no longer need to combine multiple pens to reach that level. You can read more about what this approval means in practice on our Wegovy new higher dose page.

One detail the raw percentages can obscure: these are averages across large trial populations. Individual responses vary, shaped by starting weight, metabolic factors and adherence to dietary changes alongside the medicine. The trial figures are your most credible benchmark, just not a personal guarantee.

Why the titration schedule is not optional

Starting at 0.25 mg and stepping up roughly every four weeks is not a formality, it exists because pushing the dose too fast reliably increases nausea, vomiting, constipation and other gastrointestinal effects. The body needs time to adapt to semaglutide's gastric-slowing action, and the titration schedule is what makes a 72-week course of treatment actually tolerable for most people.

There is a practical question our prescribers hear regularly: can someone start on a higher dose to see results faster? The short answer is no, and starting on a higher dose of Wegovy carries real risks of dose-related side effects that are unpleasant enough to push people off treatment altogether. A slower climb that keeps you on track produces better outcomes than a faster one you can't sustain.

For those already on treatment elsewhere, a dose increase still requires prescriber review. At nume, our GPhC-registered prescribers look at evidence of your current dose before any progression, a step that takes minutes online but protects you from changes made without the full picture. If you want to understand the full schedule from first pen to maintenance, our Wegovy doses page sets it out clearly.

The 7.2 mg dose: who it is and is not for

The MHRA approved the 7.2 mg semaglutide dose specifically for adults with a BMI of 30 or above, under the weight-management licence. It is not available to those in the BMI 27–29.9 range, even with a weight-related condition, under this particular approval, that distinction matters when a prescriber is considering it for you. The MHRA's announcement on 14 April 2026 sets out these boundaries precisely.

The 20.7% average weight-loss figure reported at this dose is striking, and it has attracted a lot of interest. But the same principle that applies at 2.4 mg applies here: the dose is part of a supervised pathway, not a shortcut. Patients must have progressed through the earlier doses before reaching 7.2 mg, and tolerability at the previous step is the clinical gate. If you have been reading about whether going beyond 2.4 mg might be relevant to your situation, that is precisely the kind of question worth putting directly to a prescriber.

For context on how Wegovy's evidence compares across the full available dose range, the higher-dose semaglutide overview covers what is known and what remains under study.

Dose, cost and what to weigh up before requesting a change

Higher doses do cost more. A higher-dose pen represents a greater monthly outlay, and that is worth factoring in before you and your prescriber discuss progression. Our Wegovy price page explains how the cost changes across doses and what is included (consultation, prescription and delivery) so there are no surprises.

If you are partway through a course and wondering whether you have plateaued because of the dose, timing matters too. Payday orders, Monday dispatches, bank-holiday gaps, treatment continuity affects results more than many people expect, and a dose-response plateau is worth distinguishing from a consistency issue before requesting a step up. A good prescriber will ask exactly that.

For a full overview of Wegovy, including how it works, who it suits and the evidence behind it, the Wegovy treatment page is the place to start. And if you are ready to talk through your current dose or eligibility for a higher one, check your eligibility with our clinical team, it is free, there is no commitment, and a real prescriber reviews your answers the same day.